Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

39 results
Display

Illuminated Chop Using an Illuminated Chopper in Cataract Surgery: on the Way to Minimal-energy Phacoemulsification

Kim J, Lee KW, Lee DY, Eom YS, Nam DH

Purpose: To minimize ultrasound power use and surgical phaco time in illuminated chop cataract surgery. Methods: The charts of patients who underwent senile cataract surgery by a single surgeon were reviewed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

Li X, Huang H, Xu B, Guo H, Lin Y, Ye S, Yi J, Li W, Wu X, Wang W, Zhan H, Xie D, Peng J, Cao Y, Pu X, Guo C, Hong H, Wang Z, Fang X, Zhou Y, Lin S, Liu Q, Lin T

PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Endoplasmic Reticulum Stress Induces MUC5AC and MUC5B Expression in Human Nasal Airway Epithelial Cells

Kim MH, Bae CH, Choi YS, Na HG, Song SY, Kim YD

OBJECTIVES: Endoplasmic reticulum (ER) stress is known to be associated with inflammatory airway diseases, and three major transmembrane receptors: double-stranded RNA-activated protein kinase-like ER kinase, inositol requiring enzyme 1, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness of L-asparaginase-based regimens compared to anthracycline-based regimens in newly diagnosed extranodal NK/T-cell lymphoma, nasal type: a single Mexican center experience

Ávila Milord AA, Aguilar Hernández MM, Demichelis Gómez R, Agreda Vásquez GP

BACKGROUND: Extranodal NK/T-cell lymphoma, nasal type (ENKTCL) has a high prevalence in Asia and Latin American countries, such as Mexico, where it encompasses 40% of all T-cell non-Hodgkin lymphomas. Historically,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent

Sekiguchi , Hamano A, Kitagawa T, Kurihara Y, Ito K, Kurimoto M, Watanabe K, Hirano K, Noto S, Yamada K, Takezako N

BACKGROUND: Waldenström Macroglobulinemia (WM) is a rare subtype of indolent B-cell lymphoma, and prospective randomized studies on WM are scarce. The R-CHOP therapy [rituximab (R), cyclophosphamide, hydroxy-doxorubicin, vincristine, and prednisone]...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma

Choi EJ, Hong JY, Yoon DH, Kang J, Park CS, Huh J, Chae EJ, Lee Y, Ryu JS, Suh C

BACKGROUND: While cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is the most commonly used chemotherapeutic regimen for patients with peripheral T-cell lymphomas (PTCLs), elderly patients are more vulnerable to associated toxicities....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
MDL-12330A potentiates TRAIL-induced apoptosis in gastric cancer cells through CHOP-mediated DR5 upregulation

Lim SC, Han SI

MDL-12330A is a widely used adenylyl cyclase (AC) inhibitor that blocks AC/cAMP signaling. In this study, we demonstrated a novel antitumor activity of this drug in gastric carcinoma (GC) cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone

Shin J, Lee JO, Choe JY, Bang SM, Lee JS

Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin’s lymphoma arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Utility Analysis for Pegfilgrastim in DLBCL Patients on R-CHOP Regimen

Jung HW, Kim JM, Min MS, Lee YM, Bang JS

OBJECTIVE: This study was designed to compare pegfilgrastim and filgrastim in diffuse large B-cell lymphoma (DLBCL) patients treated with a rituximab with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (R-CHOP) regimen in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prophylactic Effect of Pegfilgrastim on Febrile Neutropenia in Patients with Non-Hodgikin's Lymphoma

Jo J, Bang JS

OBJECTIVE: Pegfilgrastim is recently introduced that is long acting G-CSF for prophylaxis of febrile neutropenia. Treatment of non-Hodgikin's lymphoma (NHL) with R-CHOP is classified with relative high risk of febrile...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth

Lee EJ, Ahn KH, Hong SC, Lee EH, Park Y, Kim BS

Lymphoma, especially non-Hodgkin's lymphoma is extremely rare in pregnancy. A 24-year-old pregnant woman was diagnosed with diffuse large B-cell lymphoma (DLBCL), a subgroup of non-Hodgkin's lymphoma, at 24 weeks' gestation,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP

Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS

Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL). The prediction of neutropenia...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Surgical Parameters and Outcomes According to the Phacoemulsification Technique

Kim S, Ko DA, Kim JY, Kim MJ, Tchah HW

  • KMID: 2338441
  • J Korean Ophthalmol Soc.
  • 2013 Sep;54(9):1353-1358.
PURPOSE: To compare intraoperative parameters and postoperative results between divide-and-conquer and multiple phaco-chop technique. METHODS: Two different techniques were performed by one operator on the patients with bilateral cataract. One eye...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Myxoid Liposarcoma with Cartilaginous Differentiation: A Case Study with Cytogenetical Analysis

Kim H, Hwangbo W, Ahn S, Kim S, Kim I, Kim CH

  • KMID: 2277447
  • Korean J Pathol.
  • 2013 Jun;47(3):284-288.
Myxoid liposarcoma is a subtype of liposarcoma. This specific subtype can be identified based on its characteristic histological and cytogenetical features. The tumor has a fusion transcript of the CHOP...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

Yi HG, Kim JS, Suh C, Kim WS, Kwak JY, Lee JS, Kim YS, Joo YD, Min YH, Lee HG, Yoon SS, Won JH, Park S, Kim HC, Kim CS

BACKGROUND: This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Expression of CHOP in Squamous Tumor of the Uterine Cervix

Chu HH, Bae JS, Kim KM, Park HS, Cho DH, Jang KY, Moon WS, Kang MJ, Lee DG, Chung MJ

  • KMID: 2277487
  • Korean J Pathol.
  • 2012 Oct;46(5):463-469.
BACKGROUND: High-risk human papillomavirus (HR-HPV) infection and abnormal p53 expression are closely involved in carcinogenesis of squamous cell carcinoma (SqCC) of uterine cervix. Recent studies have suggested that virus-induced endoplasmic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas

Kim JE, Yoon DH, Jang G, Lee DH, Kim S, Park CS, Huh J, Kim WS, Park J, Lee JH, Lee SI, Suh C

BACKGROUND: Bortezomib targets molecular dysregulation of nuclear factor-kappaB activation and cell cycle control, which are characteristic features of diffuse large B-cell lymphoma (DLBCL). We evaluated the safety and efficacy of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Primary cutaneous B-cell lymphoblastic lymphoma in an elderly man

Cho SY, Lee SS, Back DH, Lim KA, Lee YR, Kang HJ

Precursor B-cell lymphoblastic lymphoma (B-LBL) is an uncommon high-grade neoplasm of immature B cells. It occurs predominantly in childhood with extranodal involvement such as skin and bone. Therefore, primary cutaneous...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy

Oh S, Koo DH, Suh C, Kim S, Park BH, Kang J, Huh J

Many predictive models have been proposed for better stratification of diffuse large B-cell lymphoma (DLBCL). Hans' algorithm has been widely used as standard to sub-classify DLBCL into germinal center B-cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

Jang G, Yoon DH, Kim S, Lee DH, Lee SW, Huh J, Suh C

BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, new predictors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr